Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy

FDA Panel Gives Thumbs Down to Novel Strategy for Switching Breast Cancer Therapy
ShareXFacebook

(MedPage Today) -- A novel strategy for switching breast cancer therapy intrigued members of an FDA advisory committee but failed to sway the panel to recommend approval of the strategy. By a 6-3 vote, the Oncologic Drugs Advisory Committee (ODAC...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement